Alzheimer is a progressive brain disorder linked to the changes in the brain, including the buildup of amyloid beta plaques. Amyloid is natural protein made by the body. Its excessive buildup can form plaques in the brain. It is believed to contribute to memory loss and other cognitive issues.
A monoclonal antibody Lecanemab (lequembi) has been approved by the FDA in early Alzheimer treatment in 2023. It has been developed by Eisai and Bigen. In July 2024, FDA approved Lilly’s Kiunla (donanemab-azbt). These drugs clear the excessive buildups of amyloid plaques. The treatment is approved for adults in early stages of Alzheimer.
In India, there are issues of access and affordability. The performance of drugs will be watched over the next few years.
A previously approved drug in 2021Aducanumab has not shown promising results in the reduction of beta amyloid plaques in brain scans. There was no improvement in patients’ condition.
Leave a Reply